Archives
-
Capillarisenol C Drives ER Stress–Dependent Autophagy
2026-09-17
The reference study identifies capillarisenol C, a bisphenol isolated from Artemisia capillaris, as an inducer of endoplasmic reticulum stress-associated cytotoxic autophagy in HepG2 and Huh7 liver cancer cells. Its pharmacological rescue and genetic experiments connect PERK–eIF2α and IRE1 activation with autophagy-dependent cell death, providing a framework for mechanistic ER stress and apoptosis research.
-
ATRX-Deficient Glioma and RTK Inhibitor Sensitivity
2026-09-17
The reference study identifies ATRX deficiency as a potential determinant of sensitivity to multi-targeted receptor tyrosine kinase and PDGFR inhibitors in high-grade glioma cells. It further reports pronounced toxicity when these inhibitors are combined with temozolomide, providing a rationale for incorporating ATRX status into glioma drug studies and clinical-trial analyses.
-
EZ Cap EGFP mRNA 5-moUTP Workflow Guide
2026-09-16
Build reliable reporter assays, LNP delivery screens, and fluorescence-based expression workflows with a Cap1-capped, 5-moUTP-modified EGFP transcript. This guide connects product handling and assay optimization to macrophage-targeted mRNA delivery research while separating validated findings from practical recommendations.
-
Golgi-Tracker Green: From Labeling to Mechanism
2026-09-16
Golgi-Tracker Green enables selective live-cell Golgi apparatus labeling with a BODIPY FL-labeled C5-ceramide design. This article explains how to use the probe as an organelle-resolved assay tool, interpret Golgi phenotypes, and distinguish imaging evidence from therapeutic mechanism.
-
Coumestrol in RA-FLS Ferroptosis Workflows
2026-09-15
Learn how Coumestrol connects estrogen receptor pharmacology with ferroptosis, mitochondrial stress, and inflammatory readouts in rheumatoid arthritis fibroblast-like synoviocytes. This workflow separates receptor-driven effects from concentration-dependent cytotoxicity while providing practical preparation, assay, and troubleshooting guidance.
-
ATF4 Enhancer Programs in Liver Fibrosis
2026-09-15
The reference study identifies a non-canonical ATF4 enhancer program that drives hepatic stellate cell activation and liver fibrosis independently of the conventional endoplasmic reticulum stress response. By combining HSC-specific genetic perturbation, enhancer-focused molecular analysis, human data, and pharmacological inhibition of ATF4 translation, the work suggests a mechanistically defined route for antifibrotic intervention.
-
Fulvestrant (ICI 182,780) Workflow Guide
2026-09-14
Build reproducible ER-antagonism experiments with Fulvestrant (ICI 182,780), from dose selection and receptor-degradation assays to chemotherapy-sensitization studies. The workflow connects breast cancer applications with a carefully bounded ER-stress insight from immune research without overstating cross-domain evidence.
-
PGF2α/PTGFR, HIF-1α, and Endometrial Breakdown
2026-09-14
A 2024 Reproductive Sciences study identifies PGF2α/PTGFR as a central regulator of endometrial breakdown and vascular permeability in a mouse menstrual-like model. By combining prostanoid measurements, receptor inhibition, vascular readouts, and chromatin immunoprecipitation, the work places HIF-1α upstream of PTGFR and provides a mechanistic framework for studying menstrual tissue remodeling.
-
Beyond Staining: Golgi Imaging for Translation
2026-09-13
Golgi-Tracker Green provides a photostable live-cell view of Golgi organization, lipid transport, and sphingolipid biology. This thought-leadership perspective connects BODIPY FL-labeled C5-ceramide imaging with emerging oncology evidence on Golgi fragmentation, while defining the assay controls and translational limits researchers should address.
-
Golgi-Tracker Green: Live-Cell Workflow Guide
2026-09-12
Golgi-Tracker Green enables selective, photostable visualization of Golgi membranes in living cells, supporting organelle dynamics, lipid transport, and sphingolipid studies. This guide translates the probe into practical labeling workflows and shows how Golgi morphology can complement cancer-stress assays without confusing imaging evidence with mechanistic proof.
-
Thapsigargin Workflows for SERCA and ER Stress
2026-09-11
Thapsigargin provides a fast, tunable way to connect SERCA inhibition with calcium imaging, endoplasmic reticulum stress, and apoptosis readouts. This practical guide translates a pulmonary inflammation study into assay-ready workflows while showing how to control dose, timing, cell context, and interpretation.
-
Berberine Hydrochloride: AMPK Assay Design
2026-09-11
Berberine hydrochloride is more than an AMPK-associated metabolic probe. This guide connects its lipid, apoptosis, and ferroptosis biology with a cross-validated cardiomyocyte assay strategy inspired by recent AMPK–mitochondrial research.
-
Pioglitazone: From PPARγ to Translational Insight
2026-09-10
Pioglitazone is more than a metabolic research reagent: it is a mechanistic probe for linking PPARγ activation with macrophage state, barrier integrity, beta cell resilience, and neuroinflammatory responses. This perspective translates recent DSS-induced inflammatory bowel disease findings into a practical framework for designing reproducible, cross-domain studies.
-
ZIF-8–PEI Platforms for mRNA Delivery
2026-09-10
The ChemRxiv study develops a ZIF-8 metal-organic framework system for mRNA encapsulation and identifies polyethyleneimine (PEI) incorporation as a solution to rapid cargo leakage. The resulting platform retained mRNA longer in biological media, supported protein expression across multiple cell lines, and enabled expression after room-temperature storage for three months, although the findings remain pre-peer-review.
-
Drug Response Metrics in Cancer: Beyond Viability
2026-09-09
Hannah R. Schwartz’s dissertation distinguishes relative viability from fractional viability to separate growth arrest from drug-induced cell death in cancer models. This framework improves interpretation of treatment response by emphasizing response proportions, timing, and orthogonal validation rather than relying on a single viability endpoint.